Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 6/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6071748 | 0.91 | PLA2G7 (0.44) | DRD2SIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL6071622 | 0.91 | ALDH1A1 (0.44) | SLC18A3HTR1ASIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL6071881 | 0.90 | LMNA (0.46) | SIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL3105559 | 0.82 | SLC18A3 (0.60) | SLC18A3 | |
| SCHEMBL1256028 | 0.79 | SIGMAR1 (0.49) | SLC18A3DRD2SIGMAR1 | |
| SCHEMBL6372139 | 0.79 | SIGMAR1 (0.49) | SLC18A3DRD2SIGMAR1 | |
| SCHEMBL3225303 | 0.79 | SIGMAR1 (0.49) | SLC18A3DRD2SIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL6072183 | 0.78 | GPR6 (0.50) | — | |
| Hydrochloric Acid SCHEMBL3233488 | 0.78 | SIGMAR1 (0.47) | SLC18A3DRD2SIGMAR1 | |
| Hydrochloric Acid SCHEMBL3233481 | 0.78 | SIGMAR1 (0.47) | SLC18A3DRD2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189628-A1 | Compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189628-A1 | Compounds useful as chemokine receptor antagonists | ACKR3, CCR5, CXCR2 | SLC18A3 2263/4885HTR1A 2591/4885DRD2 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.